These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 24008674

  • 1. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
    Barker HE, Bird D, Lang G, Erler JT.
    Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674
    [Abstract] [Full Text] [Related]

  • 2. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
    Dinca SC, Greiner D, Weidenfeld K, Bond L, Barkan D, Jorcyk CL.
    Breast Cancer Res; 2021 May 19; 23(1):56. PubMed ID: 34011405
    [Abstract] [Full Text] [Related]

  • 3. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
    Zhu G, Wang L, Meng W, Lu S, Cao B, Liang X, He C, Hao Y, Du X, Wang X, Li L, Li L.
    Theranostics; 2021 May 19; 11(19):9198-9216. PubMed ID: 34646366
    [Abstract] [Full Text] [Related]

  • 4. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
    Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH.
    Carcinogenesis; 2009 Oct 19; 30(10):1660-9. PubMed ID: 19625348
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
    Hong X, Yu JJ.
    Int J Oncol; 2019 May 19; 54(5):1676-1690. PubMed ID: 30816490
    [Abstract] [Full Text] [Related]

  • 8. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.
    Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT.
    Cancer Res; 2011 Mar 01; 71(5):1561-72. PubMed ID: 21233336
    [Abstract] [Full Text] [Related]

  • 9. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
    Lv GQ, Zou HY, Liao LD, Cao HH, Zeng FM, Wu BL, Xie JJ, Fang WK, Xu LY, Li EM.
    Biochem Cell Biol; 2014 Oct 01; 92(5):379-89. PubMed ID: 25275797
    [Abstract] [Full Text] [Related]

  • 10. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
    Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, Gibbons DL.
    Oncogene; 2017 Apr 06; 36(14):1925-1938. PubMed ID: 27694892
    [Abstract] [Full Text] [Related]

  • 11. LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway.
    Wen X, Liu Y, Bai Y, Li M, Fu Q, Zheng Y.
    Int J Mol Med; 2018 Dec 06; 42(6):3530-3541. PubMed ID: 30320382
    [Abstract] [Full Text] [Related]

  • 12. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
    Chang J, Nicolau MM, Cox TR, Wetterskog D, Martens JW, Barker HE, Erler JT.
    Breast Cancer Res; 2013 Dec 06; 15(4):R67. PubMed ID: 23971878
    [Abstract] [Full Text] [Related]

  • 13. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1.
    Kim BR, Dong SM, Seo SH, Lee JH, Lee JM, Lee SH, Rho SB.
    Cell Signal; 2014 Sep 06; 26(9):1765-73. PubMed ID: 24863880
    [Abstract] [Full Text] [Related]

  • 14. Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome.
    Matsuo A, Tanida R, Yanagi S, Tsubouchi H, Miura A, Shigekusa T, Matsumoto N, Nakazato M.
    Eur J Pharmacol; 2021 Feb 05; 892():173754. PubMed ID: 33248114
    [Abstract] [Full Text] [Related]

  • 15. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
    Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, Tsang FH, Lo RC, Shi J, Zheng YP, Wong CM, Ng IO.
    Hepatology; 2014 Nov 05; 60(5):1645-58. PubMed ID: 25048396
    [Abstract] [Full Text] [Related]

  • 16. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.
    Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL.
    Cancer Res; 2013 Sep 01; 73(17):5336-46. PubMed ID: 23856251
    [Abstract] [Full Text] [Related]

  • 17. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
    Brekhman V, Lugassie J, Zaffryar-Eilot S, Sabo E, Kessler O, Smith V, Golding H, Neufeld G.
    FASEB J; 2011 Jan 01; 25(1):55-65. PubMed ID: 20802105
    [Abstract] [Full Text] [Related]

  • 18. LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling.
    Zhang C, Zhu M, Wang H, Wen J, Huang Z, Chen S, Zhao H, Li H.
    Sci Rep; 2021 Aug 23; 11(1):17020. PubMed ID: 34426599
    [Abstract] [Full Text] [Related]

  • 19. The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling.
    Shinde AV, Humeres C, Frangogiannis NG.
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan 23; 1863(1):298-309. PubMed ID: 27825850
    [Abstract] [Full Text] [Related]

  • 20. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
    de Jong OG, van der Waals LM, Kools FRW, Verhaar MC, van Balkom BWM.
    J Cell Physiol; 2019 Jul 23; 234(7):10260-10269. PubMed ID: 30387148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.